DiCarlo Andrea, Button Jonathan, Cassatt David, Chang Arthur, Finklea Lauren, Iyer Narayan, Moroni Maria, Rios Carmen, Rudokas Michael, Satyamitra Merriline, Taliaferro Lanyn, Winters Thomas, Homer Mary
Radiation and Nuclear Countermeasures Program, Division of Allergy, Immunology, and Transplantation, https://ror.org/043z4tv69National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA.
Inorganic and Radiation Analytical Toxicology Branch, Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Disaster Med Public Health Prep. 2025 Jul 21;19:e199. doi: 10.1017/dmp.2025.12.
Since the early 2000s, the US Government has made purposeful investments to help ensure medical preparedness should a radiological or nuclear incident occur within its borders. This focused support of products to diagnose, mitigate, and treat radiation-induced bodily injuries that would be anticipated during a radiation public health emergency has involved many departments, ranging from multiple agencies within the Department of Health and Human Services to the Department of Defense. The intent of this manuscript is to convey information both on products that have been approved by the US Food and Drug Administration for radiation injuries during a radiation incident, as well as promising approaches under advanced stages of development. These products impact multiple organ systems (e.g., bone marrow, gastrointestinal tract, lungs, kidneys, skin) and have been tested for efficacy in a number of different small and large preclinical animal models. The successful development of these models, methods, products, and devices discussed herein demonstrate the importance of an intentionally collaborative, "one-government" approach to fostering radiation research, while also showcasing the need for critical public-private partnerships - all to ensure the safety of the public should the unthinkable occur.
自21世纪初以来，美国政府已进行了有目的的投资，以帮助确保在其境内发生放射性或核事件时的医疗准备。这种对用于诊断、减轻和治疗辐射公共卫生紧急情况期间预期的辐射引起的身体损伤的产品的重点支持涉及许多部门，从卫生与公众服务部内的多个机构到国防部。本手稿的目的是传达有关已获得美国食品药品监督管理局批准用于辐射事件期间辐射损伤的产品的信息，以及处于开发后期的有前景的方法。这些产品会影响多个器官系统（如骨髓、胃肠道、肺、肾脏、皮肤），并已在许多不同的小型和大型临床前动物模型中进行了疗效测试。本文讨论的这些模型、方法、产品和设备的成功开发证明了采取有意协作的“一个政府”方法促进辐射研究的重要性，同时也展示了关键的公私伙伴关系的必要性——所有这些都是为了在不可想象的事情发生时确保公众的安全。
